Explore
Validate
LearnPAB3040
antibody from Abnova Corporation
Targeting: FGFR1
BFGFR, CD331, CEK, FLG, FLT2, H2, H3, H4, H5, KAL2, N-SAM
Western blot
ELISAAntibody data
- Antibody Data
- Antigen structure
- References [3]
- Comments [0]
- Validations [0]
Submit
Validation data
Reference
Comment
Report error
- Product number
- PAB3040 - Provider product page
- Provider
- Abnova Corporation
- Proper citation
- Abnova Corporation Cat#PAB3040, RRID:AB_1574862
- Product name
- FGFR1 polyclonal antibody
- Antibody type
- Polyclonal
- Antigen
- A synthetic peptide (conjugated with KLH) corresponding to C-terminus of human FGFR1.
- Reactivity
- Human
- Host
- Rabbit
- Vial size
- 100 µg
- Storage
- Store at 4°C. For long term storage store at -20°C.Aliquot to avoid repeated freezing and thawing.
Submitted references Expression patterns of epidermal growth factor receptor and fibroblast growth factor receptor 1 mRNA in fetal human brain.
Differential tyrosine phosphorylation of fibroblast growth factor (FGF) receptor-1 and receptor proximal signal transduction in response to FGF-2 and heparin.
Alternatively spliced FGFR-1 isoform signaling differentially modulates endothelial cell responses to peroxynitrite.
Fu L, Abu-Khalil A, Morrison RS, Geschwind DH, Kornblum HI
The Journal of comparative neurology 2003 Jul 21;462(2):265-73
The Journal of comparative neurology 2003 Jul 21;462(2):265-73
Differential tyrosine phosphorylation of fibroblast growth factor (FGF) receptor-1 and receptor proximal signal transduction in response to FGF-2 and heparin.
Lundin L, Rönnstrand L, Cross M, Hellberg C, Lindahl U, Claesson-Welsh L
Experimental cell research 2003 Jul 1;287(1):190-8
Experimental cell research 2003 Jul 1;287(1):190-8
Alternatively spliced FGFR-1 isoform signaling differentially modulates endothelial cell responses to peroxynitrite.
Jiao J, Greendorfer JS, Zhang P, Zinn KR, Diglio CA, Thompson JA
Archives of biochemistry and biophysics 2003 Feb 15;410(2):187-200
Archives of biochemistry and biophysics 2003 Feb 15;410(2):187-200
No comments: Submit comment
No validations: Submit validation data